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Lung cancer is the leading cause of cancer death in the United States and ﬁve-year survival remains low. Numerous studies
have shown that chronic inﬂammation may lead to progression of carcinogenesis. As a result of inﬂammatory stimulation,
arachidonic acid (AA) metabolism produces proliferation mediators through complex and dynamic interactions of the products
of the LOX/COX enzymes. One important mediator in the activation of the AA pathways is the nuclear protein PPARγ. Targeting
LOX/COX enzymes and inducing activation of PPARγ have resulted in signiﬁcant reduction of cell growth in lung cancer cell lines.
However, speciﬁc COX-inhibitors have been correlated with an increased cardiovascular risk. Clinical applications are still being
explored with a novel generation of dual LOX/COX inhibitors. PPARγ activation through synthetic ligands (TZDs) has revealed a
great mechanistic complexity since eﬀects are produced through PPARγ-dependent and -independent mechanisms. Furthermore,
PPARγ could also be involved in regulation of COX-2. Overexpression of PPARγ has reported to play a role in control of invasion
and diﬀerentiation. Exploring the function of PPARγ, in this new context, may provide a better mechanistic model of its role in
cancer and give an opportunity to design a more eﬃcient therapeutic approach in combination with LOX/COX inhibitors.
Copyright © 2008 J. Tauler and J. L. Mulshine. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
LungcanceristheleadingcauseofcancerdeathintheUnited
States. Despite increasing amount of eﬀort on lung cancer
research, ﬁve-year survival is still around 15% [1].
Growing evidence suggests that molecular pathways
involved in chronic inﬂammation may contribute the pro-
gression of carcinogenesis [2, 3]. Arachidonic Acid (AA)
metabolism is intimately involved in the inﬂammatory
response. Its deregulation in epithelial cancers has been
regarded as an early step in the transformation process
[4, 5]. AA is released from the membrane by phospholipidic
enzymes, mainly through cPLA2α activity [6]. AA could be
metabolized by two major pathways: lipoxygenase (LOX)
pathway producing hydroxy derivatives and leukotrienes
and the cyclooxygenase (COX) pathway producing various
prostaglandins. Overexpression of LOX and COX enzymes
has long been associated with tumor progression [6–8], and
targets for those pathways have been a primary interest in
research for therapeutics agents [9–11]. However, speciﬁc
COX-2 inhibitors have been associated with cardiovascular
toxicity [12–15]. It has also been reported that products
of the LOX pathway and inhibitors of this pathway may
induce activity of peroxisome-proliferator-activated receptor
gamma (PPARγ)[ 9, 16, 17].
PPARγ is a member of the nuclear-hormone-receptor
superfamily characterized as having a role in lipid
metabolism and adipose diﬀerentiation [18]. Several
synthetic ligands activate PPARγ a n dr e d u c ec e l lg r o w t hb y
inducing apoptosis in lung cancer [19, 20]. Combination
therapy of 5-LOX inhibitor, PPARγ ligand, and PPARγ
binding partner has resulted in an additive eﬀect on
cell growth decrease and induction of apoptosis [21].
However, synthetic PPARγ ligands such as thiazolidinedione
derivatives (TZDs), a class of antidiabetic drugs, are also
responsible of PPARγ-independent eﬀects [22, 23]. TZDs
compounds (pioglitazone, rosiglitazone, trosiglitazone,
ciglitazone) have shown interesting clinical activity in
diabetes and metabolic syndrome but also have been
associated with rare but signiﬁcant clinical toxicities
[24, 25].2 PPAR Research
New COX/LOX inhibitors have been recently reported
and initially these drugs showing a more favorable GI and
cardiovascular tolerability [26]. Exploring the potential of
these new agents, together with a more comprehensive
mechanistic model of the PPARγ function, may provide a
solid foundation for a better design of novel combination
therapies for lung cancer.
2. INHIBITION OF LOX/COXPATHWAYS
Two isoforms of (COX) enzymes have been identiﬁed
and targeted for their clinical and pharmacological interest
[27, 28]. Characterization of COX-1 and COX-2 enzymes
led to a proposed model where COX-1 was constitutively
expressed and COX-2 was an inducible enzyme activated in
inﬂammatory response [29, 30]. Overexpression of inducible
COX-2 has also been reported in malignant conditions
associated to cell growth, protection against apoptosis, and
induction of angiogenesis in lung cancer [31–34]. Selective
COX-2 inhibitors have reduced cell growth and increased
apoptosis in lung cancer cell lines [32, 35, 36]. However,
increased cardiovascular risk has been associated with selec-
tive inhibition of COX-2 [12–15].
LOX pathway is more complex since at least six diﬀerent
enzymes have been identiﬁed in humans, and it has not
been as extensively developed for clinical applications [37].
Studies of LOX expression and activities in normal and
cancerous lesions have shown that 15-LOX-1 and 15-LOX-2
are usually expressed in normal tissues and benign lesions,
whereas 5-LOX and 12-LOX are absent in normal epithe-
lia and constitutively expressed in epithelial cancers such
as lung, colon, skin, esophageal, pancreatic, and prostate
cancers [38]. Targeting 5-LOX with speciﬁc inhibitors or by
inhibition of 5-lipoxygenase activating protein (FLAP) has
resulted in decreased cell growth and increased apoptosis
in lung and breast cancer cell lines [39]. In that report,
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diversion of the metabolic products from 5-LOX to other
LOX (12-LOX and 15-LOX) and COX pathways. Substrate
of inhibited 5-LOX is metabolized by the other available
enzymes of both LOX and COX pathways. This result has
beendescribedasendoperoxideshunting[39].Thisproperty
of the AA pathways adds another layer of complexity to
this mechanism. To address this complexity, Hong et al.
[40] analyzed, in epithelial cancer cell lines, the correlation
between expression of AA metabolizing enzymes and eﬀect
on cell growth of speciﬁc enzyme inhibitors. No correlation
was observed for inducible enzymes (LOX-12, LOX-15, and
COX-2). However, LOX inhibitors have a more potent eﬀect
on cell growth in vitro than COX inhibitors on constitutively
expressed enzymes, LOX-5, and COX-1 [40]. Of interest,
pan-COX inhibitor ketorolac did not inhibited oral cancer
growth in vitro, but it was associated with signiﬁcant
reduction of heterotransplant growth in vivo [11]. Cytokine-
producing inﬂammatory cells are present in the in vivo assay.
Stimulated macrophages and other inﬂammatory cells are
able to produce a variety of cytokines which could promote
growth diﬀerentially on clonal populations of epithelial cells.
Hong et al. [11] have suggested that IL-6 plays, through
STAT3 signaling, an important role in oral cancer regulation
in a paracrine and autocrine way. This report suggests a
potential role for inﬂammatory cells stimulating cancer cell
growth by COX-driven cytokine production.
Recent animal studies have shown COX-2 constitutive
expression in normal tissues, where it plays a role in gastric
mucosal protection, renal homeostasis, and endothelial
PGI2 production [41, 42]. This result, along with the
previously described risk of thrombotic complication after
selective inhibition of COX-2, motivated the search for an
alternative strategy [43]. Since inhibition of one pathway
of the AA metabolism might induce the activity of the
alternate pathway, a dual inhibition of both LOX and COX
pathways has been proposed as a new approach to improve
clinical utility [44]. Moreover, inhibition of COX-2 increases
production of leukotrienes (LTs), especially in the gastric
mucosa. Given the proinﬂammatory eﬀects of LTs and their
deleterious eﬀects on gastric mucosa, dual inhibition of LOX
and COX pathways might improve gastric tolerability [45].
On the other hand, free unmetabolized AA may induce
a concentration-dependent apoptosis on cancer cells [46].
Therefore,blockingLOX/COXpathwayssimultaneouslymay
prevent recruitment of alternate pathways within the AA
pathway and may lead to an accumulation of AA that could
increase apoptosis induction.
The use of combination of LOX and COX speciﬁc
inhibitors has been described in colon and pancreatic
cancer models [47, 48]. Recently, Schroeder et al. [49]
have reported that treatment of A549 lung cancer cell line
and transformed cell 1198, derived from BEAS-2B, with
a triple combination of clinical relevant concentrations of
celecoxib (COX inhibitor), MK886, and REV 5901 (both
LOX inhibitors) resulted in signiﬁcant suppression of growth
and cell death induction in both cell lines. Interestingly,
premalignant cells, derived from BEAS-2B, revealed a greater
sensitivity to this LOX/COX inhibitors combination than
malignant cells A549. This result raises the possibility
that combination of AA metabolism inhibitors might be
more eﬀective in precancerous states than in lung cancer
therapy.
However, designing a single compound that might target
both LOX and COX pathways is a strategy that oﬀers several
beneﬁts in terms of cost, risk, and adverse eﬀects [50]. By
using diﬀerent approaches, a number of new compounds
able to target LOX-5 and COX-2 have been designed but to
date limited data is available concerning their potential as
antitumorigenic agents [51]. First generation of compounds
showing dual inhibition of LOX-5 and COX-2 such as
Benoxaprofen is not longer in use due to their liver toxicity
[52]. A new generation of compounds has been developed
oﬀering a more balanced inhibition of LOX-5 and COX-
2 enzymes by acting as a substrate competitor. Licofelone
is one of the most promising candidates and is currently
on phase-III clinical trials for treatment of osteoarthritis
as anti-inﬂammatory drug [26]. Licofelone inhibits LOX-
5, COX-1, and COX-2, decreases production of PGs and
LTs [53, 54], and presents lower GI toxicity compared to
nonsteroidal anti-inﬂammatory drugs (NSAIDs) naproxen
and rofecoxib [55, 56]. Interestingly, it has been reportedJ .T a u l e ra n dJ .L .M u l s h i n e 3
recently that Licofelone inhibits LOX/COX pathways and
induces apoptosis in HCA-7 colon cancer cells [57].
3. PPARγ ACTIVATION
Active PPARγ forms a heterodimer with retinoid X receptor
RXR [22, 58, 59]. Coactivators and corepressors interact
with the PPARγ-RXR heterodimer which binds speciﬁc
regions known as PPRE (PPARγ response elements) within
promoter of target genes. Diﬀerent interactions of coac-
tivators and corepressors with PPARγ are responsible for
important changes on the transcription pattern of target
genes. Some natural ligands of PPARγ have been identiﬁed
such as leukotrienes, prostaglandin D2, prostaglandin J2
(15d-PGJ2), and some polyunsaturated fatty acids. In addi-
tion, antidiabetic drugs, such as rosiglitazone, ciglitazone,
pioglitazone, and trosiglitazone, included in the group
of thiazolidinediones (TZDs), are also ligands of PPARγ.
Activation of PPARγ in NSCLC by TZDs has induced cell
growth arrest and apoptosis [60, 61]a n da ﬀects expression
of genes such as PTEN, ﬁbronectin, and integrin alpha 5
[62–64]. However, PPARγ ligands have shown eﬀects on
NSCLC cell lines that remain elusive to understand with
our current notions of PPARγ mechanism of action. For
instance, rosiglitazone inhibits cell growth by increasing
phosphorylation of AMPKα and reducing phosphorylation
of p70S6K. Treatment with PPARγ antagonist, GW9662, has
no eﬀect on AMPKα and p70S6K phosphorylation status
[65].
PPARγ could also be regulated from upstream elements
of the AA pathway; interestingly, it has been reported that
cPLA2α, responsible of AA release from the membrane,
aﬀects PPARγ activity and modulates expression of COX-2
and IL-8 through PPARγ response elements [66, 67].
4. LOX/COX PATHWAYS AND PPARγ CROSS-TALK
Deregulation of important elements of the AA pathway
has been observed in tumor progression in several reports
as shown in Figure 1 [4, 5]. Targeting overexpression of
inducible enzymes, 5-LOX and COX-2 enzymes, as a way
t oc o n t r o lc e l lp r o l i f e r a t i o nw a saﬁ r s tl o g i c a ls t e p .H o w -
ever, as we have previously discussed, downregulation of
one pathway of the AA metabolism may induce, through
endoperoxide shunting, the other AA pathways, balancing
the initial eﬀect [68–72].
Aﬀecting the LOX/COX pathway has also an eﬀect on
the activity of PPARγ. Inhibition of 5-LOX by MK886
results in activation of PPARγ in breast and lung cancer
cell lines [9, 21]. Inhibition of COX-2 by celecoxib reduces
PGE2 production, downregulates cPLA2α expression in lung
cancer cell lines, but also induces PPARγ expression and
activity [73, 74]. On the other hand, PPARγ ligand ciglita-
zonemaymodulateCOX-2expressionandPGE2production
throughaPPARγ-independentmechanism.Thus,ithasbeen
speculated that ciglitazone could suppress transcriptional
factors involved in COX-2 mRNA production. It has also
been suggested that ciglitazone could downregulate COX-2
through a histone deacetylase mechanism [75].Furthermore,
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Figure 1: Inﬂammatory products stimulate cPLA2α which
increases levels of AA available to be metabolized by the
LOX/COX pathways. LOX/COX enzymes’ products, leukotrienes
and prostaglandins, induce cell proliferation. Natural ligands for
PPARγ are also produced by the LOX/COX pathways. Activation
of PPARγ balances the eﬀect of leukotrienes and prostaglandins
inducing apoptosis through various mechanisms. However, acti-
vation of PPARγ may also induce COX-2 and IL-8 expressions.
Furthermore, overexpression of PPARγ may decrease invasion and
induce diﬀerentiation from a mesenchymal to an epithelial-like
phenotype.
PPARγ ligands rosiglitazone and pioglitazone decrease PGE2
by upregulating 15-hydroxyprostaglandin dehydrogenase
independently of PPARγ and COX-2 [76].
MK886, inhibitor of FLAP (5-lipoxygenase activating
protein), results in inhibition of 5-LOX and induction of
PPARγ activity [9]. Induction of PPARγ might be a direct
eﬀect of MK886 [77] or an indirect eﬀect as a result of
changes in the equilibrium of AA available for each diﬀerent
LOX enzymes after inhibition of 5-LOX. Thus, production
of 15-HETE might increase which could induce PPARγ
expression [16, 17]. An interesting example of the double
eﬀect,inhibitionof5-LOXandactivationofPPARγ,hasbeen
provided by Avis et al. [21] showing that a combination of
low-dose MK886, ciglitazone (PPARγ ligand), and retinoic
Xr e c e p t o r( R X R α; transcriptional partner of PPARγ), inter-
acting in a superadditive manner, causes an inhibition of cell
growth in lung cancer cell lines A549 and H1299. Moreover,
a novel compound, LY293111, an LTB4 receptor antagonist
and inhibitor of 5-LOX, is able to induce PPARγ as well [78].
LY293111 has proved to be eﬀective in reducing cell growth
in diﬀerent types of cancer such as pancreatic, colon, and
lymphoma[79–83].However,noresultshavebeenpublished
so far in lung cancer.
InductionofPPARγ by15-LOXmetabolitesandbyCOX-
2 inhibitors and PPARγ eﬀects on COX-2 activity, among
other results, are pointing out a cross-talk between eﬀectors
of the AA pathway (LOX and COX products) and PPARγ
activity. Deregulation of this cross-talk is thought to allow
tumor progression.4 PPAR Research
5. OPTIMIZING THERAPEUTIC EFFECTS OF
THE LOX/COX/PPARγ CROSS-TALK
Despite the great eﬀort in research in lung cancer basic
biology and cancer early detection and prevention, there
has been no signiﬁcant improvement in ﬁve-year survival.
As we have been previously described, several reports are
showing that combination therapy against enzymes of the
AAmetabolismhasadramaticpotentialinchemoprevention
and chemotherapy [21, 49, 51, 57]. Moreover, new drugs,
such as Licofelone, designed to aim at a dual inhibition of
the LOX and COX pathways, have proved to be eﬀective in
reducing growth in cancer cell lines. Interestingly, a recently
published report, that uses a mathematical model to study
the interactions of the AA metabolic network, has revealed
that a dual inhibitor against LOX/COX is more eﬀective
than a combination of single COX and LOX inhibitors
[84]. A successful attempt to reduce cell growth in cancer,
through the AA metabolic pathway, may have great potency
ifinvolvesinhibitionofboththeLOXandCOXpathwaysand
activation of PPARγ.M o r er e s e a r c hi sn e e d e di nt h i ss u b j e c t
to conﬁrm the safety of dual inhibitors regarding GI toxicity
and cardiovascular tolerability. In addition, eﬃciency of dual
inhibitors in preventing cancer growth and inducing cell
death has to be proved in other cancers especially in lung
cancer.
To manage the systemic toxicity for lung cancer therapy,
we have used a regional delivery strategy [85, 86]. With
aerosolized drug delivery, there is direct delivery of the
therapeutic agent to the target transforming cell population
injured by chronic exposure tobacco smoke. Despite attrac-
tive results with relevant animal models and early clinical
experience [87], this approach has not received serious com-
mercial attention. However, aerosolized drug delivery has
the appeal of avoiding certain important complications of
PPARγ activation, related to the complicated enterohepatic
metabolism of these drugs [88].
Increasing evidence suggests that PPARγ acts as a key
control element of the AA pathway. Pawliczak et al. [66, 67]
haveshownthatcPLA2α,responsibleoftheactivationofAA,
regulates PPARγ expression and COX-2 and IL-8 expressions
through PPARγ in lung cancer cell lines. This last result is
especially intriguing since it suggests that PPARγ can also
stimulate growth in addition of its role as suppressor of cell
growth and inductor of apoptosis. Despite several evidence
of the mainstream activity of PPARγ, always in the context of
an increased expression of the LOX pathway and/or COX-
2, we should consider a more general role for PPARγ as
feedback regulator of the AA pathway.
In this context, using PPARγ agonists, such as the TZDs,
has provided a considerable amount of information about
the PPARγ function. But it has also revealed the great com-
plexity of their indirect eﬀects not related to PPARγ [22, 23].
One approach to study PPARγ function, without the inter-
ference of TZDs, would be to overexpress PPARγ in NSCLC.
Overexpression of PPARγ has no eﬀect on proliferation
but it aﬀects anchorage-independent growth, invasiveness
and induces a diﬀerentiation from a mesenchymal to an
epithelial-like phenotype [89]. In the same vein, some recent
studies are suggesting a role for PPARγ in control of anoikis
byinteractingwithfocaladhesionproteins[90,91].Tobetter
understand the PPARγ function, a more direct approach
might be to study the eﬀect of overexpression and silencing
of PPARγ on mechanisms of cell proliferation and apoptosis.
Generating such data could enable the development of a
mechanisticmodelthatcouldexplaintheineﬃcientresponse
of PPARγ, in the context of overexpression of the LOX/COX
pathways, in lung cancer. This model may also allow a
better understanding of LOX/COX interaction and PPARγ
function.Asaresultofthisapproach,acombinationtherapy,
basedondualinhibitorsoftheLOX/COXpathways,couldbe
developed in a more rationale fashion and provide a better
result in chemoprevention and chemotherapy.
6. CONCLUSION
With considering the clinical signiﬁcance of AA metabolism,
it may be useful to partition certain aspects of this complex
biology. For example, it is known that COX products are
constitutivelyrequiredforthemaintenanceofnormalgastric
epithelium, and from a clinical tolerance perspective, it
would be good not to interfere with this function.
Aswehavediscussed,chronicinjuryinitiatesanexcessive
release of cytokines and other inﬂammatory mediators
such as arachidonic acid metabolism products which could
trigger carcinogenesis. In devising therapeutic strategies,
with the arachidonic acid products, greater attention to
the impact of levels of mediators may be rewarding. For
beneﬁcial eﬀects with carcinogenesis, it would be of interest
to evaluate if reduction, rather than complete elimination,
in levels of arachidonic acid products would be eﬃcacious
without incurring clinical toxicity. Moreover, exploring the
eﬀects of PPARγ activity in diﬀerent contexts, such as
anoikis, could provide relevant mechanistic information
about PPARγ function that might allow an improved design
of combination therapies.
Important opportunities exist to reduce the occurrence
of low frequency but signiﬁcant hepatic toxicity by consider-
ingtheuseofaerosolizeddrugdeliverystrategies.Thiswould
potentiallygreatlyenabletheuseofcombinationapproaches,
asdiscussedinthisreview,forearlylungcancermanagement
applications.
Developmentofrobustclinicalpharmacologytools, such
as the assay for urinary PGM, could allow for a precise and
adaptive method to deﬁne optimal dosing for LOX/COX
inhibitors. This approach may provide an important new
opportunity in learning how to more eﬀectively exploit the
eﬀects of inhibiting LOX and COX pathways, in combination
with PPARγ activation, on control of proliferation and
apoptosis in lung cancer.
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